Why Did GE HealthCare Shares Decline Amid High Trading Volume?

Highlights,GE HealthCare Technologies operates within the healthcare equipment sector.,GEHC stock recently saw a slight decrease in trading value.,Fin...

Kazia Therapeutics (NASDAQ: KZIA) Provides Update on FDA Meeting Reg...

Highlights,FDA aligns with Kazia on Phase 3 study design for paxalisib in glioblastoma.,3.8-month survival improvement in GBM-AGILE trial strengthens...

Analyst Insights on Stryker's Strategic Position and Future

Headlines,Stryker's Strategic Outlook: Insights and Updates,Analyst Revisions and Future Perspectives,Stryker's Position in the Healthcare Landscape,S...

Avantor's Short Interest Drop Signals Shifting Market Sentiment

Headlines,Avantor experiences a decrease in short interest.,Significant institutional investments in Avantor shares.,Analysts have varying views, but...

Amgen stock price formed a death cross: will it rebound in 2025?

The Amgen stock price suffered a harsh reversal in the fourth quarter of 2024 as its weight loss drug failed to excite. After peaking at $341 in July,...

Select Medical (NYSE:SEM) A Deep Dive into Financials

Highlights,Significant changes in holdings by institutional investors.,Spanning critical illness recovery, rehabilitation, and outpatient clinics.,Hig...

Weight-loss drug investments: why 2025 could be a game-changer

Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped Novo Nordisk A/S (CPH: NO...

Eli Lilly and Company (NYSE:LLY) Continues to Lead in Healthcare Inn...

Highlights,Marjorie Taylor Greene (R-Georgia) buys shares in Eli Lilly.,Eli Lilly shows strong stock performance with solid revenue growth.,Eli Lilly...

Short Interest Decline and Investor Moves in Fresenius Medical Care...

Highlights,Short interest in Fresenius Medical Care decreased by 5.1% in December.,Hedge funds, including Wulff Hansen & Co., significantly raised the...

Emergent BioSolutions (NYSE:EBS) Stock Performance and Analyst Cover...

Highlights,Emergent BioSolutions now covered by HC Wainwright.,Institutional investors hold a strong 78.4% stake in Emergent BioSolutions.,The company...

Why Are Longeveron’s Quarterly Results Raising Eyebrows This Year?

Highlights,Longeveron,(NASDAQ:LGVN),operates in the biotechnology sector, focusing on regenerative medicine.,The company reported improved earnings co...

Why Is Cellectis Struggling to Break Out of Its Slump?

Highlights,Cellectis focuses on gene editing solutions for advanced healthcare innovations.,The company operates within the biotechnology sector, deve...

Analyzing Pfizer's (NYSE:PFE) Dividend Growth Amid Earnings Decline

Highlights,Pfizer increases dividend for the upcoming year to $0.43.,Dividend payout ratio expected to decrease but could still remain sustainable.,Co...

VolitionRx Ltd (NYSE:VNRX) A Leader in Epigenetic Blood Test Innovat...

Highlights,VolitionRx focuses on epigenetics to aid in early cancer and disease detection.,Company’s market cap stands at $56.99 million with a P/E ra...

Why Is This AML Trial Raising Serious Questions About Current Treatm...

Highlights,Hemogenyx initiates clinical trial for HG-CT-1 in treating R/R AML.,Focus on evaluating safety and effects on survival and disease progress...

CEL-SCI (NYSE: CVM) Announces Public Offering to Support Multikine D...

Highlights,CEL-SCI plans to raise capital to fund continued development of Multikine cancer therapy.,ThinkEquity appointed as sole placement agent for...

CVS Health Faces Challenges as Earnings Decline Weighs on Stock Perf...

Headlines,CVS Health's performance has seen significant challenges, with recent declines raising concerns.,The company's price-to-earnings ratio indic...

The Impact of Market Volatility on Waters Corporation (NYSE:WAT)

Highlights,Impressive 17% price growth in recent months for Waters Corporation.,Fair valuation of the stock, priced 8.9% below its intrinsic value.,Hi...

Viracta Therapeutics Explores Strategic Alternatives Amid Trial Clos...

Highlights,Viracta Therapeutics announces it is exploring strategic alternatives, including mergers, licensing, or sales.,The company has decided to v...

Chemed’s (NYSE:CHE) Stock Hits a 52-Week Low Amid Financial Struggle...

Highlights,Chemed’s stock hits a 52-week low of $517.44, down 1.1%.,Company missed analysts’ earnings expectations for the latest quarter.,Dividend pa...